Bevacizumab

Evidence Level: L5 Predicted Indications: 70

Quick Overview

Item Value
Drug Name Bevacizumab
DrugBank ID DB00112
Brand Names (EU) Avastin, Avzivi, Lytenava, Mvasi
Evidence Level L5
Predicted Indications 70
Top Prediction Score 99.90%

Approved Indication (EMA)

Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patien

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 epiglottis neoplasm 99.90% DL
2 benign neoplasm of tongue 99.90% DL
3 tumor of testis and paratestis 99.90% DL
4 benign neoplasm of hypopharynx 99.90% DL
5 benign neoplasm of floor of mouth 99.90% DL
6 cervical neuroblastoma 99.89% DL
7 cystic neoplasm 99.89% DL
8 nasal cavity inverting papilloma 99.89% DL
9 mesenchymoma 99.89% DL
10 schwannoma of jugular foramen 99.89% DL
11 thyroglossal duct cyst 99.89% DL
12 inner ear neoplasm 99.89% DL
13 ductal or ductular proliferation 99.89% DL
14 bronchial adenomas/carcinoids childhood 99.89% DL
15 chondroid hamartoma 99.89% DL
16 non-seminomatous lesion 99.89% DL
17 odontogenic cyst 99.89% DL
18 pre-malignant neoplasm 99.89% DL
19 jugular foramen meningioma 99.89% DL
20 vestibulocochlear nerve neoplasm 99.89% DL

Showing top 20 of 70 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.